FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308370165> ?p ?o ?g. }

• W4308370165 endingPage "810" @default.
• W4308370165 startingPage "801" @default.
• W4308370165 abstract "Abstract Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021, the US Food and Drug Administration approved the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) FL after ≥2 lines of therapy. Priced at $373 000, CAR T-cell therapy is potentially curative, and its cost-effectiveness compared with other modern R/R FL treatment strategies is unknown. We developed a Markov model to assess the cost-effectiveness of third-line CAR T-cell vs standard of care (SOC) therapies in adults with R/R FL. We estimated progression rates for patients receiving CAR T-cell and SOC therapies from the ZUMA-5 trial and the LEO CReWE study, respectively. We calculated costs, discounted life years, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) of CAR T-cell vs SOC therapies with a willingness-to-pay threshold of $150 000 per QALY. Our analysis was conducted from a US payer’s perspective over a lifetime horizon. In our base-case model, the cost of the CAR T-cell strategy was $731 682 compared with $458 490 for SOC therapies. However, CAR T-cell therapy was associated with incremental clinical benefit of 1.50 QALYs, resulting in an ICER of $182 127 per QALY. Our model was most sensitive to the utilities associated with CAR T-cell therapy remission and third-line SOC therapies and to the total upfront CAR T-cell therapy cost. Under current pricing, CAR T-cell therapy is unlikely to be cost-effective in unselected patients with FL in the third-line setting. Both randomized clinical trials and longer term clinical follow-up can help clarify the benefits of CAR T-cell therapy and optimal sequencing in patients with FL." @default.
• W4308370165 created "2022-11-11" @default.
• W4308370165 creator A5020217070 @default.
• W4308370165 creator A5025952434 @default.
• W4308370165 creator A5035304428 @default.
• W4308370165 creator A5058524502 @default.
• W4308370165 creator A5062298311 @default.
• W4308370165 creator A5067497285 @default.
• W4308370165 creator A5088820789 @default.
• W4308370165 creator A5090669888 @default.
• W4308370165 date "2023-03-03" @default.
• W4308370165 modified "2023-09-26" @default.
• W4308370165 title "Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma" @default.
• W4308370165 cites W1576880656 @default.
• W4308370165 cites W1982967337 @default.
• W4308370165 cites W2044932116 @default.
• W4308370165 cites W2058056848 @default.
• W4308370165 cites W2059212936 @default.
• W4308370165 cites W2085346499 @default.
• W4308370165 cites W2094536157 @default.
• W4308370165 cites W2096552494 @default.
• W4308370165 cites W2133104890 @default.
• W4308370165 cites W2134023402 @default.
• W4308370165 cites W2221495331 @default.
• W4308370165 cites W2337724293 @default.
• W4308370165 cites W2469109222 @default.
• W4308370165 cites W2519603001 @default.
• W4308370165 cites W2786946813 @default.
• W4308370165 cites W2795192878 @default.
• W4308370165 cites W2800595080 @default.
• W4308370165 cites W2891879965 @default.
• W4308370165 cites W2892153379 @default.
• W4308370165 cites W2912319186 @default.
• W4308370165 cites W2918342502 @default.
• W4308370165 cites W2925270992 @default.
• W4308370165 cites W2948047060 @default.
• W4308370165 cites W2966575895 @default.
• W4308370165 cites W2967335421 @default.
• W4308370165 cites W2997593504 @default.
• W4308370165 cites W3024978145 @default.
• W4308370165 cites W3033943641 @default.
• W4308370165 cites W3083020245 @default.
• W4308370165 cites W3092484545 @default.
• W4308370165 cites W3109233120 @default.
• W4308370165 cites W3119254082 @default.
• W4308370165 cites W3130692824 @default.
• W4308370165 cites W3154997741 @default.
• W4308370165 cites W3168168786 @default.
• W4308370165 cites W3198258548 @default.
• W4308370165 cites W4200248834 @default.
• W4308370165 cites W4220992493 @default.
• W4308370165 cites W4224224975 @default.
• W4308370165 cites W4281571809 @default.
• W4308370165 cites W4281673467 @default.
• W4308370165 doi "https://doi.org/10.1182/bloodadvances.2022008097" @default.
• W4308370165 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36342852" @default.
• W4308370165 hasPublicationYear "2023" @default.
• W4308370165 type Work @default.
• W4308370165 citedByCount "5" @default.
• W4308370165 countsByYear W43083701652023 @default.
• W4308370165 crossrefType "journal-article" @default.
• W4308370165 hasAuthorship W4308370165A5020217070 @default.
• W4308370165 hasAuthorship W4308370165A5025952434 @default.
• W4308370165 hasAuthorship W4308370165A5035304428 @default.
• W4308370165 hasAuthorship W4308370165A5058524502 @default.
• W4308370165 hasAuthorship W4308370165A5062298311 @default.
• W4308370165 hasAuthorship W4308370165A5067497285 @default.
• W4308370165 hasAuthorship W4308370165A5088820789 @default.
• W4308370165 hasAuthorship W4308370165A5090669888 @default.
• W4308370165 hasBestOaLocation W43083701651 @default.
• W4308370165 hasConcept C10882517 @default.
• W4308370165 hasConcept C112930515 @default.
• W4308370165 hasConcept C121608353 @default.
• W4308370165 hasConcept C126322002 @default.
• W4308370165 hasConcept C142424586 @default.
• W4308370165 hasConcept C143998085 @default.
• W4308370165 hasConcept C1491633281 @default.
• W4308370165 hasConcept C2777058707 @default.
• W4308370165 hasConcept C2777701055 @default.
• W4308370165 hasConcept C2779338263 @default.
• W4308370165 hasConcept C3019080777 @default.
• W4308370165 hasConcept C3875195 @default.
• W4308370165 hasConcept C54355233 @default.
• W4308370165 hasConcept C64332521 @default.
• W4308370165 hasConcept C71924100 @default.
• W4308370165 hasConcept C86803240 @default.
• W4308370165 hasConcept C87355193 @default.
• W4308370165 hasConceptScore W4308370165C10882517 @default.
• W4308370165 hasConceptScore W4308370165C112930515 @default.
• W4308370165 hasConceptScore W4308370165C121608353 @default.
• W4308370165 hasConceptScore W4308370165C126322002 @default.
• W4308370165 hasConceptScore W4308370165C142424586 @default.
• W4308370165 hasConceptScore W4308370165C143998085 @default.
• W4308370165 hasConceptScore W4308370165C1491633281 @default.
• W4308370165 hasConceptScore W4308370165C2777058707 @default.
• W4308370165 hasConceptScore W4308370165C2777701055 @default.
• W4308370165 hasConceptScore W4308370165C2779338263 @default.
• W4308370165 hasConceptScore W4308370165C3019080777 @default.

• next